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Introduction
SPECIFIC receptors, located in the plasma mem-branes of cells, are crucially involved in mediating
the acute and chronic effects of a wide variety of hor-
mones, drugs, growth factors, antigens, and other ligands.
Some membrane receptors are involved in transporting
various important molecules into the cell by a process
known as receptor-mediated endocytosis. An important
insight which has emerged from recent research is that
both the function and subcellular distribution of many
such receptors are dynamically regulated.
Phosphorylation/dephosphorylation represents per-
haps the most intensively studied reversible covalent
modification of enzymes which is known to have regu-
latory significance (1, 2). Considerably more is known
about the kinases than the phosphatases. Only recently
has it begun to be appreciated that the function of
noncatalytic proteins, such as receptors, may also be
regulated in this way. We review here the important
plasma membrane receptor systems thus far studied
whose function and/or cellular trafficking has been dem-
onstrated to be regulated by phosphorylation. Available
information suggests a number of principles which may
be generally applicable as well as several testable hy-
potheses.
/?-Adrenergic Receptor-Coupled Adenylate
Cyclase
The jS-adrenergic receptor-coupled adenylate cyclase
system may be considered to be prototypical of a wide
variety of receptors which are coupled to their effector
systems via guanine nucleotide regulatory (G) proteins.
G proteins represent a family of closely related proteins
which are heterotrimeric consisting of GTP binding and
hydrolyzing a-subunits as well as /3- and 7-subunits (3-
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5). Receptors may either stimulate adenylate cyclase via
the stimulatory guanine nucleotide regulatory protein
(G8) or inhibit it via the inhibitory guanine nucleotide
regulatory protein (Gi). It is now readily apparent that
some forms of regulation of adenylate cyclase may be
achieved through phosphorylation of its protein compo-
nents. One of the most extensively investigated forms of
this type of regulation is that of desensitization. Desen-
sitization is defined as a process through which prolonged
exposure of target cells to hormone, drug, or neurotrans-
mitter agonists results in a diminished cellular respon-
siveness to further agonist stimulation.
Desensitization of 0-adrenergic receptor-coupled
adenylate cyclase is generally divided into two major
categories (6-8). One form is referred to as agonist spe-
cific or homologous and is distinguished by the fact that
only stimulation by 0-adrenergic agonists is attenuated.
Conversely, agonist-nonspecific or heterologous desen-
sitization is characterized by diminished responsiveness
to additional receptor agonists and to nonreceptor acti-
vators such as guanine nucleotides and fluoride ion.
Investigations of homologous desensitization have dem-
onstrated sequestration or down-regulation of the recep-
tors away from the cell surface in addition to an uncou-
pling of receptor-adenylate cyclase interaction (6-8). Ho-
mologous desensitization does not appear to be mediated
by cAMP as this form of refractoriness can be demon-
strated in the absence of cAMP generation (6-8). Het-
erologous desensitization, by contrast, does not involve
receptor sequestration or down-regulation but instead is
primarily associated with functional uncoupling of the
receptors from adenylate cyclase. Moreover, heterologous
desensitization appears to be mediated, at least partially,
by cAMP (6-8). Since heterologous desensitization is
associated with decrements in fluoride ion and guanine
nucleotide-stimulated activities (effectors which bypass
the receptors) this form of desensitization must, at a
minimum, involve alterations in either the regulatory
proteins and/or the catalytic moiety of adenylate cyclase.
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Recent studies have, in fact, demonstrated that the
stimulatory and perhaps the inhibitory guanine nucleo-
tide regulatory proteins (Gs and Gj, respectively) are
functionally modified in heterologous desensitization.
Kassis and Fishman (9) demonstrated that Gs extracted
from heterologously desensitized fibroblasts and recon-
stituted into S49 eye" cell membranes (S49 cyc~ cells
lack G8 but possess the other components of adenylate
cyclase) was functionally impaired relative to controls.
Similarly, heterologous desensitization induced by pros-
taglandin Ex in liver (10) and by human CG in ovaries
(11) results in an impaired functionality of Gs as deter-
mined with S49 eye" membrane reconstitution. In con-
trast, Rich et al. (12) have reported that glucagon-in-
duced heterologous desensitization in MDCK cells was
not associated with G8 alterations but instead involved
increases in the apparent levels of the inhibitory guanine
regulatory protein, Gi. This suggests that alterations in
the G8/Gi stoichiometry may be another mechanism by
which heterologous desensitization is achieved.
Additional evidence for a functional alteration in G8
in heterologous desensitization has come from studies
with avian erythrocytes. Briggs et al. (13) found that
when Gs was extracted from catecholamine-desensitized
turkey erythrocytes and carefully quantitated by labeling
with [32P]NAD+ and cholera toxin, desensitization re-
sulted in a significant reduction in the ability of Gs to
reconstitute adenylate cyclase activity in S49 cyc~ mem-
branes. Although heterologous desensitization can ap-
parently result in impaired G8 functionality, this does
not exclude other potential lesions in the adenylate cy-
clase system. In fact, the observation that catecholamine-
stimulated adenylate cyclase activity is desensitized by
about 50% whereas the fluoride ion and guanine nucleo-
tide activities are reduced by only 10-20% after agonist-
induced desensitization is indicative of other processes
which occur as well (6,13).
Indeed, using [32P]orthophosphate incorporation, it
has been shown that during the heterologous desensiti-
zation in both avian and amphibian erythrocytes, the /3-
adrenergic receptor undergoes phosphorylation (14-16).
Sibley et al. (15) have investigated this phosphorylation
process in detail using turkey erythrocytes. In these cells,
the /3-adrenergic receptor is stoichiometrically phospho-
rylated under basal conditions containing 0.7-1.0 mol
phosphate/mol receptor with this stoichiometry increas-
ing to 2-3 mol/mol upon maximal desensitization (15).
This phosphorylation occurs exclusively on serine resi-
dues in the receptor (16, 17). We have also shown that
the phosphate/receptor stoichiometry is tightly corre-
lated with the degree of desensitization (15). For in-
stance, the time courses for receptor phosphorylation
and adenylate cyclase desensitization are identical as are
the rates of resensitization and the return of the phos-
phate/receptor stoichiometry to control levels (15).
Moreover, incubation of the cells with membrane-perme-
able cAMP analogs causes submaximal phosphorylation
of the /3-adrenergic receptor which is correlated with the
partial desensitization of adenylate cyclase which these
analogs evoke (15). These data thus indicate that in
erythrocytes, heterologous desensitization is tightly cor-
related with phosphorylation of the 0-adrenergic recep-
tor.
Since cAMP analogs can reproduce the catecholamine-
induced receptor phosphorylation and desensitization in
avian (15) and amphibian erythrocytes (16), then pre-
sumably the cAMP-dependent protein kinase is involved
in this desensitization. In fact, Benovic et al. (18) have
recently demonstrated a cAMP-mediated phosphoryla-
tion of mammalian lung 0-adrenergic receptor that is
similar to the process exhibited by erythrocytes. Using
pure receptor and pure c AMP-dependent protein kinase,
it is shown that isoproterenol enhanced the rate of re-
ceptor phosphorylation (on serine residues) by about 2-
fold. Reconstitution of the phosphorylated receptor with
the G8 protein demonstrated diminished agonist-pro-
moted receptor-mediated stimulation of the GTPase ac-
tivity compared with controls. Thus, the cAMP-depend-
ent protein kinase-promoted phosphorylation is func-
tionally significant. Since any hormone or drug that
raises intracellular cAMP levels will presumably lead to
such /3-adrenergic receptor phosphorylation, this type of
regulation is of the heterologous type.
A fascinating question concerning heterologous desen-
sitization is why incubation of avian erythrocytes with
cAMP analogs produces only partial effects (15). One
hypothesis, suggested by Benovic et al. (18), is that in
order to obtain maximal phosphorylation of the /3-adre-
nergic receptor, agonist occupancy must occur. Another
possibility is that the receptor phosphorylation is not
completely mediated by cAMP and that other protein
kinase systems may phosphorylate the /3-adrenergic re-
ceptor as well. In this regard, we (19) and others (20)
have shown that phorbol esters, compounds which po-
tently activate protein kinase C, are capable of stimulat-
ing /3-adrenergic receptor phosphorylation concomitantly
with adenylate cyclase desensitization. Interestingly, in
duck erythrocytes (19) the phorbol ester-induced recep-
tor phosphorylation is nonadditive with that produced
by isoproterenol, suggesting a common mechanism or
pathway of action.
Recently, protein kinase C has been shown to directly
phosphorylate the purified /3-adrenergic receptor in vitro
albeit to a lower stoichiometry than that of the cAMP-
dependent protein kinase (21). The phosphorylation by
protein kinase C occurs on serine residues and is not
enhanced by agonist occupancy of the receptor. Impor-
tantly, the sites on the receptor that are phosphorylated
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by protein kinase C and the cAMP-dependent protein
kinase appear to be identical as determined by peptide
mapping techniques (21).
The relationship of the protein kinase C and cAMP-
dependent protein kinase phosphorylation sites has been
further elucidated by recent molecular cloning and se-
quence analysis of the j82-adrenergic receptor (22). Figure
1 shows the j82-adrenergic receptor as it is proposed to be
organized in the plasma membrane. As can be seen in
Fig. 1, there are two sites on the receptor consisting of
the general amino acid sequence Arg-Arg-X-Ser, which
represents a consensus recognition site for the cAMP-
dependent protein kinase (23). Both of these sequences
also contain a basic amino acid (lysine) either at or close
to the carboxy-terminal side of the relevant serine resi-
due, which renders these excellent recognition sites for
protein kinase C as well (24).
It thus appears as if protein kinase C and the cAMP-
dependent protein kinase both phosphorylate the 0-ad-
renergic receptor on identical sites. The phosphorylation
by the cAMP-dependent protein kinase is enhanced by
receptor agonist occupancy and represents a classical
negative feedback regulatory loop. Phosphorylation of
the /3-adrenergic receptor by protein kinase C may rep-
resent a cross talk pathway whereby receptor systems
which stimulate phosphatidylinositol turnover and acti-
vate protein kinase C can negatively modulate adenylate
cyclase-coupled receptors. In support of this hypothesis
is the observation that muscarinic receptor agonists have
been shown to promote /3-adrenergic receptor desensiti-
zation in the heart where muscarinic receptors are cou-
pled to phosphatidylinositol hydrolysis (25).
In summary, the molecular mechanisms which are
thought to be involved in heterologous desensitization
are shown in Fig. 2. In this form of desensitization,
receptor function is regulated by phosphorylation in the
absence of receptor sequestration or down-regulation.
This covalent modification serves to functionally uncou-
ple the receptors, that is, to impair their interactions
with the guanine nucleotide regulatory proteins. Several
protein kinases seem to be capable of promoting
phosphorylation of the receptors including the cAMP-
dependent kinase and protein kinase C. In addition to
the receptor modification, heterologous desensitization
seems to be associated with functional modifications
(phosphorylation?) at the level of the nucleotide regula-
tory proteins (G8 and GO.
The mechanisms by which agonists promote homolo-
gous desensitization of the /3-adrenergic receptor also
appear to involve receptor phosphorylation. Evidence for
this was first obtained using amphibian erythrocytes
where /?-adrenergic agonists were shown to promote ho-
mologous desensitization of adenylate cyclase and phos-
phorylation of /3-adrenergic receptor (26). The agonist-
induced receptor phosphorylation is pharmacologically
specific and stoichiometric, occurring to about 2 mol
phosphate/mol receptor. Prostaglandin Ei does not pro-
mote /3-adrenergic receptor phosphorylation, although
this hormone elevates cAMP levels in these cells. This
suggests that the observed receptor phosphorylation is
not mediated by the cAMP-dependent protein kinase.
Additional evidence that protein kinase A is not involved
in homologous-induced receptor phosphorylation has
come from studies using S49 lymphoma cells (27). It was
observed that in the S49 mutant cell lines cyc~ and kin",
which are deficient in the G8 protein and c AMP-depend-
ent protein kinase, respectively, agonists promoted 0-
adrenergic receptor phosphorylation to the same degree
as in wild type cells. These results indicate that 1)
receptor-G8 coupling is not necessary for receptor phos-
phorylation to occur—agonist occupancy is sufficient;
and 2) the receptor phosphorylation is not mediated by
the cAMP-dependent protein kinase.
Benovic et al. (28-30) have recently identified and
Adrenergic Receptor
FIG. 1. Structure of the /8-adrenergic re-
ceptor as it is proposed to be organized
in the plasma membrane. The sites of
phosphorylation by the cAMP-depend-
ent protein kinase (and probably protein
kinase C) are indicated. The solid circles
represent the serine- and threonine-rich
region in the carboxy terminus which
may serve as sites of /3ARK phosphor-
ylation (see text).
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FIG. 2. Heterologous desensitization mechanisms of adenylate cyclase.
purified a novel protein kinase with phosphorylates the
i8-adrenergic receptor and may be involved in homolo-
gous desensitization. Referred to as the j8-adrenergic
receptor kinase (or /3ARK), it is quite ubiquitous in
mammalian tissues thus far examined and appears to be
cytosolic. It has the unique property of phosphorylating
only the agonist-occupied form of the receptor. The
unoccupied or antagonist-occupied receptor is not a sub-
strate for the enzyme. 0ARK is distinct from other
protein kinases such as the cAMP-, cGMP-, Ca2+/cal-
modulin-, and Ca2+/phospholipid-dependent protein ki-
nases. Moreover, jSARK does not phosphorylate such
general kinase substrates as casein or histones. Upon
addition of 0-adrenergic agonist to the cell, 0ARK is
translocated from the cytosol to the plasma membrane,
where it phosphorylates the agonist-occupied receptor
(31). The exact sites of 0ARK phosphorylation on the /8-
adrenergic receptor are not yet known, although, in anal-
ogy with the rhodopsin/rhodopsin kinase system (see
below), the serine/threonine-rich carboxy terminus (Fig.
1) is a likely region.
A clear consequence of j8-adrenergic receptor phos-
phorylation in homologous desensitization is a functional
uncoupling of the receptors from the G8 proteins. Sibley
et al. (32) demonstrated that phosphorylated jS-adrener-
gic receptors purified from amphibian erythrocytes are
functionally impaired in reconstituting receptor-Gs in-
teractions in phospholipid vesicles when compared to
controls. Similarly, purified /3-adrenergic receptor which
has been phosphorylated by /? ARK shows an impairment
of function (J. L. Benovic et al., manuscript in prepara-
tion).
The molecular events which may be involved in ho-
mologous desensitization of the 0-adrenergic receptor are
shown in Fig. 3. Phosphorylation and uncoupling of the
receptors from adenylate cyclase activation occur within
minutes after agonist occupancy of the receptors (27,
32). Shortly thereafter the receptors become sequestered
or internalized within the cells into low density mem-
brane particles or vesicles, although the exact nature of
this sequestered compartment is currently unknown, as
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FIG. 3. Homologous desensitization of j8-adrenergic receptor-coupled
adenylate cyclase.
are the mechanisms of receptor translocation (6). For
example, it is not known whether coated pits are involved
or whether the receptor phosphorylation event triggers
the redistribution of the receptors from the plasma mem-
brane. Within the sequestered compartment the recep-
tors become dephosphorylated and functionally regen-
erated (32). High levels of /S-adrenergic receptor phos-
phatase activity appear to be associated with the seques-
tered membrane compartment (32). When agonist is
removed or its concentration decreased sufficiently, the
receptors can redistribute back to their basal levels in
the plasma membranes.
As reviewed above, phosphorylation of the receptor
components of the adenylate cyclase system appears to
be important in dampening the hormonal signal. Recent
studies, however, have suggested that phosphorylation of
the catalytic components of the enzyme system may
serve as an amplification mechanism. This was first
suggested from experiments that involved treating cells
with phorbol esters, compounds that potently activate
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protein kinase C (33), and examining their effects on
adenylate cyclase activity. It was observed that phorbol
ester treatment resulted in enhanced basal adenylate
cyclase activity as well as that stimulated by a variety of
hormonal and nonhormonal effectors (34-39). This am-
plification effect has also been demonstrated by the
direct addition of activated protein kinase C to plasma
membranes (40).
Using amphibian erythrocytes, we have demonstrated
that incubation of these cells with phorbol esters results
in a dramatic 100-300% amplification of /3-adrenergic
agonist-, prostaglandin-, guanine nucleotide-, as well as
Mn2+-, and forskolin-stimulated enzyme activities (34).
The observation that the forskolin- and Mn2+-stimulated
activities are increased is especially interesting since
these compounds can directly stimulate the catalytic unit
of adenylate cyclase. This suggests that protein kinase C
may phosphorylate the catalytic unit resulting in ampli-
fied activity. In fact, using erythrocytes, we have dem-
onstrated that activation of protein kinase C with phor-
bol esters results in stoichiometric phosphorylation of
the catalytic unit of adenylate cyclase (41). Under basal
conditions there is no observable phosphate incorporated
into the catalytic unit purified from [32P]-labeled cells,
however, from phorbol ester-treated cells, the catalytic
unit is phosphorylated to about 3 mol phosphate/mol
enzyme. We have also shown that purified protein kinase
C can directly phosphorylate the adenylate cyclase cat-
alytic unit purified from bovine brain (41). This protein
kinase C-catalyzed phosphorylation of the adenylate cy-
clase catalytic unit and amplification of enzyme activity
may provide a physiological mechanism by which recep-
tor systems that promote phosphatidylinositol turnover
and protein kinase C activation can modulate receptor
systems coupled to adenylate cyclase.
Other G Protein-Coupled Receptors
It has become increasingly apparent that diverse bio-
logical phenomena are characterized by adaptive proc-
esses analogous to the desensitization observed in 0-
adrenergic receptor-coupled adenylate cyclase systems.
Not surprisingly, many of the other G protein-coupled
receptors display desensitization phenomena qualita-
tively similar to those described above. Thus far, little
information is available concerning the molecular mech-
anisms involved. It will be of interest to see whether
these are identical to those uncovered for the /3-adrener-
gic receptors.
A number of receptors, including ai-adrenergic and
muscarinic cholinergic, which are coupled via G proteins
to phosphatidylinositol turnover and protein kinase C
activation (33, 42) demonstrate regulatory phenomena
similar to adenylate cyclase-coupled receptors. Most no-
tably, the ax-adrenergic receptor-stimulated phosphati-
dylinositol turnover response in cultured smooth muscle
cells has been shown to be desensitized by phorbol ester
treatment (43, 44). Moreover, this desensitization is as-
sociated with phosphorylation of the ai-adrenergic recep-
tor (44). More recently, it has been shown that ax-
adrenergic agonists also promote ai-adrenergic receptor
desensitization, sequestration, and phosphorylation in a
temporally correlated fashion (45). Unlike the situation
for the adenylate cyclase-coupled /8-adrenergic receptors,
there is as yet no evidence for specific receptor kinases
involved in these phosphorylation reactions. In fact, it
appears that protein kinase C itself directly phosphoryl-
ates the ai-adrenergic receptor and that the rate but not
the extent of this reaction is enhanced by agonist occu-
pancy (21). This is analogous to the cAMP-dependent
protein kinase-mediated phosphorylation of the 0-adre-
nergic receptor (18). A classical feedback loop thus pre-
sumably operates whereby diacylglycerol, generated by
agonist stimulation of phosphatidylinositol turnover, ac-
tivates protein kinase C, which phosphorylates and de-
sensitizes the ai-adrenergic receptor. The cAMP-de-
pendent protein kinase will also directly phosphorylate
the ai-adrenergic receptor in vitro, although agonists do
not promote this reaction (21).
The situation for the muscarinic cholinergic receptor
seems quite analogous to that of the «i-adrenergic recep-
tor. Desensitization of muscarinic receptor-stimulated
phosphatidylinositol hydrolysis and receptor down-reg-
ulation has been observed in response to cholinergic
agonist or phorbol ester stimulation (46-50). Further-
more, Kwatra and Hosey (51) have recently demon-
strated muscarinic receptor phosphorylation in cardiac
tissue in response to agonist activation. The protein
kinase(s) involved in this reaction has not yet been
identified.
An additional G protein-coupled receptor system
which demonstrates well characterized adaptive phe-
nomena is the rhodopsin system in retinal rod outer
segments. As reviewed in detail elsewhere (22, 52), this
system is structurally and functionally analogous to
hormone-activated adenylate cyclase. The analogous
components are a photon of light instead of hormone,
rhodopsin instead of receptor, a GTP-binding and hy-
drolyzing protein termed transducin instead of G8, and
a cyclic GMP (cGMP) phosphodiesterase, which con-
trols retinal concentrations of cGMP, instead of the
catalytic unit of adenylate cyclase. Rhodopsin undergoes
a phosphorylation reaction that is catalyzed by a specific
kinase termed rhodopsin kinase (53-57). Phosphoryla-
tion by rhodopsin kinase requires the light (agonist)
activated form of rhodopsin and occurs on multiple serine
and threonine residues within the carboxy terminus of
rhodopsin (58). Phosphorylation of rhodopsin results in
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an impaired ability of rhodopsin to interact with trans-
ducin. This system is thus desensitized by an agonist-
promoted phosphorylation reaction that uncouples the
receptor from its GTP-binding regulatory protein. Al-
though phosphorylation of rhodopsin will reduce its in-
teraction with transducin, an additional protein is re-
quired for complete uncoupling of this system. This
protein, referred to as 48K protein, S antigen, or arrestin,
only binds to the phosphorylated form of rhodopsin (59,
60). This observation raises the interesting hypothesis
that there may be an analogous 48K protein in the
adenylate cyclase system whose action is necessary to
express the full functional effects of receptor phosphor-
ylation.
The picture that emerges from these findings is of a
variety of pathways by which G protein-coupled recep-
tors are regulated. There are classical feedback regula-
tory loops, such as the protein kinase A phosphorylation
of the /3-adrenergic receptor or protein kinase C phos-
phorylation of the ai-adrenergic receptor. The rates of
these reactions are enhanced by agonist occupancy of the
receptors. Cross-talk pathways also exist by which, for
example, protein kinase C can phosphorylate the aden-
ylate cyclase-coupled /?-adrenergic receptor or protein
kinase A the ai-adrenergic receptor. These reactions are
not promoted by agonist occupancy of the substrate
receptor. Although their physiological regulatory signif-
icance is less clear, these reactions could play an impor-
tant amplification role in tissues where a physiological
or biochemical response of the target cell is reciprocally
controlled by hormones using two distinct signal trans-
duction pathways. Finally, there are specific receptor
kinases, such as rhodopsin kinase and /8ARK, which
phosphorylate and desensitize specific receptors in a
completely agonist-dependent fashion. Such kinases lead
only to agonist-specific or homologous desensitization
since agonist-promoted conformational changes in the
receptor are required to transform them into substrates
for the regulatory enzyme.
Insulin Receptors
Insulin induces a wide variety of biological effects in
target cells leading to alterations in cellular metabolism
and growth. These actions are mediated by specific high
affinity cell surface receptors. Insulin receptors are in-
tegral membrane glycoproteins comprised of two a-sub-
units (Mr a 130,000) and two 0-subunits (Mr s 90,000)
linked by disulfide bonds (reviewed in Refs. 61 and 62).
Insulin appears to interact with the a-subunit of the
receptor which results in enhanced tyrosine kinase activ-
ity which is intrinsic to the |8-subunit. Both the a- and
0-subunits are known to be derived from a single glyco-
sylated precursor protein Mr = 190,000. Recently, com-
plementary DNAs (cDNAs) encoding the precursor have
been cloned which predict a polypeptide consisting of
either 1,370 (63) or 1,382 (64) amino acids. The a-subunit
comprises the N-terminal portion of the precursor, fol-
lowed by an enzyme cleavage site and then the /3-subunit
containing a single transmembrane spanning sequence.
The /3-subunit also contains a protein kinase domain
which exhibits homology with the epidermal growth fac-
tor (EGF) receptor and the src family of tyrosine kinases.
A schematic representation of the insulin receptor is
shown in Fig. 4.
Although the physiological effects of insulin receptor
stimulation are well known, the initial biochemical sig-
nals have been difficult to elucidate. One of the earliest
measurable responses to insulin stimulation, however, is
that of receptor phosphorylation. Kasuga et al. (65, 66)
initially demonstrated that insulin stimulates phosphor-
ylation of the 0-subunit of the receptor in 32P-labeled
lymphocytes and hepatoma cells. Similar results have
been observed using isolated adipocytes (67) and rat
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FIG. 4. Schematic representation of the insulin receptor. Regions of
high cysteine concentration are shown as hatched boxes, transmem-
brane domains as solid boxes, and tyrosine kinase domains as open
boxes.
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hepatocytes (68). In most cells, under basal conditions
the 0-subunit contains predominantly phosphoserine
and to a lesser extent phosphothreonine. Upon addition
of insulin to the cells, increased levels of phosphoserine
and phosphothreonine are observed in addition to phos-
phorylation of tyrosine residues in the j3-subunit (67, 68-
75). Interestingly, Pang et al. (71) have shown that the
insulin-stimulated tyrosine phosphorylation temporally
precedes the increased serine phosphorylation of the /3-
subunit. Peptide mapping of the phosphorylated /3-sub-
units from intact cells indicates the presence of multiple
sites of serine, and to a lesser extent threonine, phos-
phorylation whereas the tyrosine phosphorylation occurs
on two to three major distinct sites (72-74). Recently,
Stadtmauer and Rosen (76) have presented evidence
suggesting that tyrosine l.lSO1 is one of the phosphoryl-
ated residues in insulin-stimulated cells (Fig. 4). In intact
cells, the a-subunit does not appear to be phosphorylated.
In contrast to intact cells, when insulin-stimulated
receptor phosphorylation is examined under cell-free
conditions, using [7-32P]ATP, phosphorylation occurs
exclusively on tyrosine residues. A large number of lab-
oratories have characterized this reaction using solubi-
lized insulin receptors in various stages of purity from a
variety of tissues (see Refs. 61, 62, and 77 for review and
references). It has been well documented that the cell-
free phosphorylation is a result of autophosphorylation
of the /3-subunit and that the insulin receptor itself is a
tyrosine kinase. Autophosphorylation of the /3-subunit
appears to be intramolecular as dilution of insulin recep-
tors does not decrease the rate of 0-subunit phosphoryl-
ation (78, 79). The /J-subunit possesses an ATP binding
site (80-82), and the cloned sequence predicts a protein
kinase domain with homology to other tyrosine kinases
(63, 64). Tyrosine phosphorylation of the a-subunit has
also been observed under cell-free conditions (83, 84);
however, as this subunit appears to be extracellular (Fig.
4), this reaction may not be physiologically significant.
Reports on the stoichiometry of insulin receptor phos-
phorylation indicate that in vitro the /3-subunit is phos-
phorylated up to 2 mol phosphate/mol receptor (78, 79).
Peptide mapping of the in vitro phosphorylated 0-subunit
indicates that there are two to three distinct sites of
tyrosine phosphorylation (72, 74, 78,79,85). In the study
of White et al. (72), two of the in vitro phosphorylation
sites corresponded to the two tyrosine phosphorylation
sites which were observed in intact cells.
Evidence is now available which indicates that the
1
 The two reported amino acid sequences for the insulin receptor
precursor differ in that the sequence of Ebina et al. (64) contains an
insertion of 12 amino acids in the carboxy terminus of the a-subunit
when compared to that of Ullrich et al. (63). In this review, we will
refer to the sequence of Ullrich et al. (63) when designating amino acid
residues.
activity of the insulin receptor tyrosine kinase is en-
hanced by tyrosine phosphorylation of its |8-subunit.
Rosen et al. (86) initially showed that autophosphoryla-
tion of the receptor results in increased tyrosine kinase
activity as measured with exogenous substrates. More-
over, after autophosphorylation, the activated tyrosine
kinase is rendered insulin independent. Dephosphoryla-
tion of the receptor with alkaline phosphatase restores
the insulin dependency of the tyrosine kinase. Other
laboratories have shown that autophosphorylation of the
receptor both in vitro (85, 87) and in intact cells (74, 88)
leads to enhanced tyrosine kinase activity of the /3-
subunit. In the studies of Yu and Czech (85) and Kwok
et al. (87) the enhanced activity correlated with the
phosphorylation of a single tryptic peptide site. •
Using antibodies directed to peptides derived from the
known sequence of the ^-subunit, Herrera and Rosen
(89) have provided evidence that tyrosines 1150 and 1316
(Fig. 4) are autophosphorylated in vitro. It was further
shown that autophosphorylation of Tyr-1150, which is
also phosphorylated in intact cells (76), is best correlated
with kinase activation. Interestingly, antibodies directed
against the sequence containing Tyr-960 block auto-
phosphorylation and thus exogenous kinase activity (90),
yet this residue does not appear to be autophos-
phorylated in vitro (76). Using microsequencing tech-
niques, Tornqvist et al. (91) have also demonstrated in
vitro autophosphorylation of tyrosine residues 1150 and
1316 as well as tyrosines 1146,1151, and 1322. Recently,
Ellis et al. (92) have demonstrated that point mutations
in tyrosines 1150 and 1151 will reduce insulin-stimulated
autophosphorylation and tyrosine kinase activity in par-
allel with a decrease in insulin-stimulated 2-deoxyglucose
uptake when expression is performed in CHO cells.
Taken together, these results argue strongly for a role of
autophosphorylation of tyrosines 1150 and 1151 in acti-
vation of tyrosine kinase activity, although the molecular
mechanism by which this activation occurs is not yet
understood.
The observation that in intact cells insulin receptors
undergo phosphorylation on serine and threonine resi-
dues in addition to tyrosine residues suggests that other
protein kinases are involved in regulating insulin recep-
tor function. A role for the cAMP-dependent protein
kinase has been suggested by Pessin et al. (93) who
showed that incubation of adipocytes with /?-adrenergic
agonists, which raise intracellular cAMP levels, inhibit
high affinity binding of insulin to its receptor. Insulin-
stimulated glucose transport is also inhibited, and these
effects are mimicked by incubation with dibutyryl-
cAMP. Haring et al. (94) have reported similar findings
and further showed that /3-adrenergic agonist treatment
of cells reduces the tyrosine kinase activity of the recep-
tor by increasing its Michaelis-Menten constant (Km)
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for ATP. Similarly, Stadtmauer and Rosen (75) demon-
strated that increasing the cAMP of IM-9 cells dimin-
ishes insulin receptor tyrosine kinase activity and that
this is correlated with increased serine and threonine
phosphorylation on the /3-subunit. Although these data
suggest that c AMP leads to attenuation of insulin action
by altering the phosphorylation state of the insulin re-
ceptor, it is not clear whether the cAMP-dependent
protein kinase directly phosphorylates the receptor. In-
spection of the amino acid sequence of the 0-subunit
indicates the absence of classic consensus recognition
sites for this enzyme (63, 64) suggesting that multiple
kinases may be involved in this modification.
Protein kinase C also appears to be involved in regu-
lating insulin receptor function. Treatment of cells with
phorbol esters, which activate protein kinase C, results
in increased phosphorylation of serine and threonine
residues in the 0-subunit (69, 73, 95, 96). In some cells,
but not others, this modification results in a reduction
in affinity of insulin for binding to the receptor. Taka-
yama et al. (69) and Haring et al. (96) have shown that
phorbol ester-induced receptor phosphorylation addi-
tionally results in a reduction of tyrosine kinase activity
of the /3-subunit. Recently, Bollag et al. (97) demon-
strated that protein kinase C can directly phosphorylate
the /3-subunit of the insulin receptor in vitro to stoichi-
ometric levels. This phosphorylation is accompanied by
a 65% reduction in the tyrosine kinase activity of the
receptor.
As noted earlier, treatment of intact cells with insulin
results in enhanced receptor phosphorylation on serine
and threonine residues. Peptide mapping experiments
indicate that these residues appear, for the most part, to
be distinct from those phosphorylated in response to
protein kinase C activation (69, 73). This may suggest
that insulin treatment leads to the activation of other
serine/threonine kinases or that insulin occupancy of the
receptor renders it a better substrate for those kinases.
Recent results have indicated that long term insulin
treatment of cells can lead to reductions in receptor
tyrosine kinase activity (98, 99) which may be linked to
the observed insulin-induced increase in serine/threo-
nine phosphorylation.
Insulin receptors thus appear to be under both positive
and negative control through phosphorylation of their 0-
subunits. One of the earliest events in insulin activation
is autophosphorylation of the #-subunit leading to en-
hanced tyrosine kinase activity toward exogenous sub-
strates. Tyr-1150 and 1151 appear to be intimately in-
volved in this phosphorylation although other tyrosine
residues cannot be ruled out as yet. In contrast, phos-
phorylation of the /3-subunit on serine and perhaps thre-
onine residues results in decreased autophosphorylation
and tyrosine kinase activity of the receptor. The serine
and threonine residues involved in this modification have
not yet been identified. A number of serine/threonine
protein kinases may be involved in this phosphorylation
including the cAMP-dependent protein kinase and pro-
tein kinase C. Whether or not insulin occupancy results
in receptor phosphorylation by additional kinases re-
mains to be determined.
Insulin-Like Growth Factor (IGF) Receptors I
and II
IGF-1 or somatomedin C is a polypeptide growth factor
with an amino acid sequence which is highly homologous
to insulin. IGF-I initiates its mitogenic response in target
cells by binding to specific receptors on the plasma
membrane. Like the insulin receptor, the IGF-I receptor
is a disulfide-linked heterotetramer that can be resolved
into Mr s= 130,000 a-subunits which bind IGF-I and Mr
= 98,000 /3-subunits which exhibit tyrosine kinase activ-
ity (100). In analogy with the insulin receptor, IGF-I
receptor a- and /3-subunits are encoded with a single Mx
= 180,000 glycosylated receptor precursor for which
cDNAs have been recently cloned and sequenced (101).
As with the receptor for insulin, the IGF-I receptor is
a tyrosine protein kinase capable of autophosphoryla-
tion. Incubation of 32P-labeled IM-9 and Hep-G2 cells
with IGF-I promotes phosphorylation on tyrosine resi-
dues of the IGF-I receptor /3-subunit (73). In addition, in
both partially and highly purified preparations of IGF-1
receptors, IGF-I stimulates phosphorylation of tyrosine
residues on the /3-subunit of the receptor (95, 102-107).
Evidence has been presented that this is an intramole-
cular reaction (105, 107). As with insulin receptors, au-
tophosphorylation of the IGF-I receptor is believed to
enhance its tyrosine kinase activity. IGF-I receptor-me-
diated phosphorylation of exogenous tyrosine-containing
substrates is enhanced by prior autophosphorylation, and
this enhancement is reversed by phosphatase treatment
of the receptor (105,107).
In intact cells, the /?-subunits of the IGF-I receptor are
constitutively phosphorylated on serine and threonine
residues (73). Incubation of cells with biologically active
phorbol esters increase this serine and threonine phos-
phorylation by about 4-fold (73, 95). In IM-9 cells, IGF-
I also promotes serine and threonine phosphorylation on
the /3-subunit, although apparently on different sites
than those observed with phorbol esters (73). The func-
tional significance of these serine and threonine phos-
phorylations is at present unclear; however, in some cells
phorbol esters have been shown to reduce IGF-I binding
activity (108).
Like IGF-I, IGF-II is a peptide hormone which is
structurally homologous with insulin. The receptor for
IGF-II is distinct from the IGF-1 receptor and is com-
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posed of a single polypeptide with Mr = 250,000 (109).
The IGF-II receptor appears to be functionally different
from insulin and IGF-I receptors in that binding of IGF-
II to its receptor does not directly trigger acute metabolic
or growth-permissive effects. Moreover, the IGF-II re-
ceptor does not appear to possess tyrosine kinase activity
(110). Rather it has been suggested that internalization
and recycling of the IGF-II receptor may be closely linked
to IGF-II action (111). Interestingly, Oka et al. (112,113)
have observed that insulin treatment of adipocytes leads
to increased numbers of IGF-II receptors in the plasma
membrane. In addition, there is a concomitant decrease
in IGF-II receptors located in a low density microsomal
membrane compartment.
Corvera and Czech (114) have investigated the molec-
ular basis of this phenomenon and demonstrated a role
for IGF-II receptor phosphorylation. They found that
under basal conditions about 80-90% of the total cellular
IGF-II receptors reside in a microsomal fraction with
10-20% being located in the plasma membrane. More-
over, the receptors in the plasma membrane are stoichi-
ometrically phosphorylated possessing 2- to 3-fold more
phosphate than those receptors in the microsome frac-
tion. Insulin treatment produces a specific and dramatic
decrease in the phosphorylation state of the plasma
membrane receptors which is correlated with the ap-
pearance of receptors on the cell surface. These data
suggest a model in which the IGF-II receptor is persist-
ently phosphorylated on the cell surface leading to inter-
nalization into a microsomal compartment where de-
phosphorylation can occur. Insulin perturbs this process
by inhibiting the IGF-II receptor kinase or activating a
phosphatase or both which leads to decreased internali-
zation and increased IGF-II receptor expression on the
cell surface. Interestingly, this model is analogous to that
describing the role of phosphorylation in /3-adrenergic
receptor sequestration and recycling (see above).
The nature of the protein kinase(s) involved in IGF-II
receptor phosphorylation is at present not known. Corv-
era et al. (110), however, have demonstrated that the
IGF-II receptor can be phosphorylated by a tyrosine
kinase in adipocyte membranes although, as mentioned
above, this is not an autophosphorylation event.
The EGF Receptor
EGF is a polypeptide mitogen which is capable of
stimulating the proliferation of a variety of epidermal
and epithelial cells (115). The receptor for EGF is a
170,000 dalton glycosylated transmembrane protein
which exhibits intrinsic tyrosine kinase activity (115,
116). Activation of the receptor with EGF leads to en-
hanced intracellular protein phosphorylation on tyrosine
residues (see Refs. 77,117, and 118 for reviews). Recent
molecular cloning of the EGF receptor indicates that it
consists of 1,186 amino acids, contains a single mem-
brane-spanning domain, and exhibits an extracellular
amino terminus and a cytosolic carboxy terminus (119-
121). The tyrosine kinase domain of the receptor is in
the cytoplasmic region and demonstrates high homology
to the transforming protein v-erb B of avian erythro-
blastosis virus (122). A schematic representation of the
EGF receptor is shown in Fig. 5. In intact cells, the EGF
receptor is constitutively phosphorylated on serine, thre-
onine, and tyrosine residues (123-125). Evidence has
accumulated suggesting that these phosphorylation sites
may be intimately linked with regulating receptor func-
tion.
Stimulation of the EGF receptor with EGF rapidly
leads to receptor autophosphorylation on tyrosine resi-
dues (reviewed in Refs. 77 and 115-118). Downward et
al. (126) have shown that tyrosine residues 1,068, 1,148,
and 1,173 in the carboxy terminus are involved in this
autophosphorylation with residue 1,173 being the most
heavily phosphorylated (Fig. 5). This reaction was shown
by Weber et al. (127) to be intramolecular in nature. Gill
and colleagues (128, 129) have suggested that this auto-
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FIG. 5. Schematic representation of the EGF receptor. Regions of high
cysteine concentration are shown as hatched boxes, the transmembrane
domain as a solid box, and the tyrosine kinase domain as an open box.
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phosphorylation enhances the tyrosine kinase activity of
the receptor. When phosphorylation of exogenous pep-
tide substrates is assayed as a function of receptor au-
tophosphorylation, tyrosine kinase activity is enhanced
by up to 3-fold at a phosphate/receptor stoichiometry of
1-2 mol/mol. High concentrations of peptide substrates
can inhibit phosphorylation of both the receptor and the
peptides, but this inhibition can be relieved by initially
autophosphorylating the receptor. These results suggest
then that autophosphorylation of the carboxy terminus
may remove an inhibitory steric constraint, thus allowing
access of exogenous substrates to the active site and
increased tyrosine kinase activity.
In contrast to the above studies, an early report by
Cassel et al. (130) indicated that EGF-induced autophos-
phorylation of the EGF receptor in A431 cell membranes
does not affect its tyrosine kinase activity. In addition,
the rate of EGF-induced exogenous peptide phosphoryl-
ation does not show a lag during the time period in which
receptor phosphorylation was" submaximal. ^Similarly,
Downward et al. (131) have provided evidence that vari-
ation in the extent of receptor autophosphorylation from
0.1-2.8 mol phosphate/mol receptor does not influence
receptor kinase activity either in purified or membrane-
bound receptor preparations. Moreover, Gullick et al.
(132) have shown that antibodies raised against synthetic
peptides containingjthe EGF receptor tyrosine autophos-
phorylation sites can inhibit autophosphorylation of the
native receptor without affecting EGF-stimulated tyro-
sine kinase activity toward exogenous substrates. In ad-
dition, Yarden and Schlessinger (133) have presented
evidence favoring an intermolecular rather than an in-
tramolecular mechanism of EGF receptor activation. It
is thus not yet clear whether receptor autophosphoryla-
tion on tyrosine residues results in enhanced tyrosine
kinase activity of the EGF receptor. It is expected that
experiments involving site-directed mutagenesis of the
relevant tyrosine residues in the EGF receptor will re-
solve this important issue. :
In addition to phosphorylation on tyrosine residues,
treatment of intact cells with EGF results in1 enhanced
phosphorylation of serine and threonine residues in the
receptor (123-125, 134). Since EGF has been shown to
promote phosphatidylinositol turnover (135, 136) gen-
erating diacylglycerol which activates protein kinase C
(137), it was proposed that this kinase phosphorylates
the receptor. Indeed, a number of studies have demon-
strated that treatment of cells with phorbol esters, which
directly activate protein kinase C, results in attenuation
of EGF binding to its receptor (138-144). Moreover,
phorbol esters induce phosphorylation of serine and thre-
onine residues in the EGF receptor in intact 32P-labeled
cells (124, 125, 134, 145, 146). Although treatment of
cells with phorbol esters enhances phosphorylation of
both serine and threonine residues, peptide mapping
experiments indicate the appearance of unique peptides
containing only phosphothreonine (124, 134, 145, 146).
Hunter et al. (145) and Davis and Czech (147) have
identified threonine 654 in the EGF receptor as the
unique site of phosphorylation in response to phorbol
esters in intact cells. This residue is located on the
cytoplasmic side of the receptor nine residues away from
the plasma membrane (Fig. 5). It is thus in an ideal
location to affect interaction between the extracellular
and intracellular domains of the receptor. Protein kinase
C added directly to A431 cell membranes will also phos-
phorylate the EGF receptor on the same sites as those
promoted by phorbol esters (134).
Phosphorylation of EGF receptors by protein kinase
C appears to inhibit receptor tyrosine kinase activity.
Cells exposed to phorbol esters exhibit decreased phos-
photyrosine levels in EGF receptors and other proteins
(124, 134, 148). These studies also demonstrated that
EGF-induced autophosphorylation of the receptor on
tyrosine residues is reduced after phorbol esters treat-
ment. Recently, Downward et al. (131) have also shown
that phosphorylation of the EGF receptor by protein
kinase C results in decreased tyrosine kinase activity
toward exogenous substrates.
As discussed previously, phosphorylation of the EGF
receptor by protein kinase C (via phorbol ester treat-
ment) results in functional alterations in EGF binding.
In some cells this is apparent as a reduction in the high
affinity component of EGF-receptor binding, whereas in
others the result is a decrease in the number of EGF
receptors at the cell surface. Davis and Czech (149) have
shown that reduction of the apparent affinity of the EGF
receptor by protein kinase C correlates with phosphor-
ylation of threonine 654 but not with phosphorylation of
other residues on the receptor. Lin et al. (150) have
further shown that mutating threonine 654 to an alanine
residue blocks phorbol ester-induced EGF receptor in-
ternalization in a cellular expression system. These data
suggest that phosphorylation of threonine 654 by protein
kinase C regulates the affinity of the receptor for EGF,
the activity of the tyrosine kinase domain, as well as the
intracellular location of the receptor.
It should be noted that the mechanisms by which EGF
induces internalization of its receptor may be distinct
from those mediated by the actions of phorbol esters.
First, phorbol esters appear to promote internalization
of EGF receptors in the absence of receptor degradation
(151, 152), whereas EGF promotes both internalization
and degradation (153). Moreover, in the study of Lin et
al. (150) the alanine 654 mutant receptors were still
internalized and degraded in response to EGF. There
thus appears to be two independent mechanisms by
which EGF receptors are internalized. One of these in-
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volves phosphorylation on threonine 654 of the receptor
and can be promoted by both phorbol esters and EGF
(154). The other, which is promoted only by EGF, also
leads to receptor degradation and may or may not involve
phosphorylation. In this regard, it is interesting that
monoclonal antibodies to the EGF receptor can promote
receptor internalization in the apparent absence of phos-
phorylation (155).
Although EGF stimulation leads to rapid autophos-
phorylation on tyrosine residues which may result in
enhanced kinase activity. EGF treatment also results in
the phosphorylation of threonine 654 (154) leading to
eventual receptor internalization and tyrosine kinase
inhibition (156). In addition to this negative feedback
loop induced by EGF, the protein kinase C-induced re-
ceptor phosphorylation may also represent a mechanism
of heterologous regulation by other hormone ligands
which activate protein kinase C. Platelet-derived growth
factor (PDGF), fibroblast growth factor, bombesin, and
vasopressin, all of which stimulate phosphatidylinositol
turnover, decrease EGF binding to its receptor (157-
161). Davis and Czech (162) have further shown that
PDGF will induce phosphorylation on threonine 654 of
the EGF receptor. Moreover, synthetic derivatives of
diacyglycerol, the endogenous activator of protein kinase
C, will promote EGF receptor phosphorylation (163-
165).
The EGF receptor is also potentially regulated through
phosphorylation by the cAMP-dependent protein kinase.
This kinase has been shown to phosphorylate membrane-
bound and purified EGF receptor on serine and threonine
residues (166, 167). Evidence that this phosphorylation
may be physiologically significant has come from studies
of Pessin et al. (93). They observed that treatment of
adipocytes with both /3-adrenergic agonists, which in-
crease intracellular cAMP levels, and with dibutyryl-
cAMP leads to a decreased affinity of the receptor for
EGF. Phosphorylation of the EGF receptor by the
cAMP-dependent protein kinase may thus lead to inhi-
bition of EGF action.
The PDGF Receptor
PDGF is one of the major mitogens found in serum
which stimulates DNA and protein synthesis as well as
amino acid uptake and phosphatidylinositol turnover in
a number of cells (168). Interestingly, PDGF is structur-
ally homologous with the product of the v-sis oncogene
(169). The PDGF receptor has been identified by affinity
cross-linking experiments as a Mr = 180,000 single poly-
peptide glycoprotein (170, 171). Like the receptors for
insulin, EGF and IGF-I, the PDGF receptor posseses
tyrosine kinase activity. Initial studies using fibroblast
membranes demonstrated that PDGF promotes the in-
corporation of phosphate into tyrosine residues of a Mr
= 180,000 protein (172-174). Pike et al. (175) and Heldin
et al. (170) subsequently provided evidence suggesting
that the phosphoprotein observed in fibroblast mem-
branes is the PDGF receptor. It was also observed that
the Mr = 180,000 protein contains phosphoserine and
phosphothreonine which are enhanced upon PDGF
treatment (175). The PDGF receptor has been recently
purified using a novel antiphosphotyrosine antibody
(176-178). These studies indicate that the Mr s= 180,000
substrate of the PDGF-stimulated tyrosine kinase is, in
fact, the PDGF receptor and like the other tyrosine
kinase receptors is capable of autophosphorylation. Very
recently, the primary structure of the PDGF receptor
has been obtained through molecular cloning techniques
(179). The single polypeptide contains an extracellular
ligand binding domain, a single membrane spanning
region, and an intracellular tyrosine kinase domain
which is homologous with other tyrosine kinases (179).
Since the functional consequences of PDGF receptor
autophosphorylation are not yet known, it will be inter-
esting to investigate whether this covalent modification
is linked to tyrosine kinase activation as suggested for
the other tyrosine kinase receptors. Similarly, it will be
important to establish a role for the phosphorylation of
the PDGF receptor on serine and threonine residues
(175) and to identify the kinase(s) involved. Since PDGF
promotes phosphatidylinositol turnover in several cell
types, it is tempting to speculate that protein kinase C
may somehow be involved in these phosphorylation
events. However, a recent report by Sturani et al. (180)
has suggested that phorbol esters do not affect PDGF
receptor function, at least in fibroblasts.
The Nicotinic Acetylcholine Receptor
The nicotinic acetylcholine receptor is an integral
membrane protein that functions as a neurotransmitter-
dependent ion channel at the vertebrate neuromuscular
junction (181). The nicotinic receptor has been most
extensively studied in the Torpedo electric organ and
exists as an oligomer of four polypeptide chains with
masses of 40 (a), 50 (0), 60 (7), and 65 (5) kilodaltons
(kD) with a stoichiometry of a2fiy8 (182). Phosphoryla-
tion of the nicotinic acetylcholine receptor has been
shown to occur both in intact cells and in vitro with as
many as nine phosphoserines being identified, distrib-
uted 1, 1, 2, and 5 among the a, /?, 7, and 8 subunits,
respectively (183). Postsynaptic membranes rich in the
nicotinic receptor appear to contain both endogenous
protein kinase (184-186) and protein phosphatase activ-
ities (187).
The endogenous protein kinases include protein kinase
C which phosphorylates the a- and 5-subunits of the
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receptor on serine residues (188). In addition, an endog-
enous tyrosine protein kinase which phosphorylates the
/?-, 7-, and 5-subunits of the receptor has been reported
(188). This kinase phosphorylates a single tryosine resi-
due on each of these subunits with stoichiometries of
approximately 0.5 mol phosphate/mol subunit attained
in postsynaptic membranes. It has also been reported
that purified pp608rc of Rous sarcoma virus as well as
A431 cell membranes, which are rich in EGF receptor,
both specifically phosphorylate purified nicotinic acetyl-
choline receptor on the #-, 7-, and 5-subunits (188).
The cAMP-dependent protein kinase (protein kinase
A) also phosphorylates the 7- and 5-subunits of the
nicotinic receptor on serine residues (189, 190). This
phosphorylation can be completely blocked by the spe-
cific inhibitor protein of the cAMP-dependent protein
kinase. Huganir and Greengard (189) have demonstrated
that the 7- and 5-subunits of the purified receptor are
phosphorylated by the catalytic subunit of protein kinase
A to stoichiometries of 1.0 and 0.89 mol phosphate/mol
receptor, respectively. Based on amino acid sequences
and subunit and substrate specificities, Huganir et al.
(188) proposed the phosphorylation sites for protein
kinase A as serine 354 (7-subunit) and serine 361 (5-
subunit). Moreover, antibodies raised against synthetic
peptides encompassing the proposed phosphorylation
sites inhibit phosphorylation of the receptor by protein
kinase A (191).
Several recent studies have provided evidence for a
functional alteration of the acetylcholine receptor when
phosphorylated by protein kinase A (192-194). Two
groups have demonstrated that treatment of rat skeletal
muscle with forskolin, a potent activator of adenylate
cyclase, leads to desensitization of nicotinic receptor
function (192-194). Moreover, Huganir et al. (193) have
provided direct evidence in a reconstituted system that
phosphorylation of the receptor by protein kinase A
increases the rate of agonist-induced desensitization of
the receptor by 7- to 8-fold. These results provide the
first direct evidence that phosphorylation regulates the
function of an ion channel receptor protein.
Intracellular Transport Receptors
Eukaryotic cells internalize many macromolecules and
nutrients by receptor-mediated endocytosis. The intra-
cellular pathways of this process have been investigated
in a variety of receptor systems (reviewed in Refs. 195
and 196). Upon binding of ligand, the receptors move to
and cluster in specialized regions of the plasma mem-
brane termed coated pits. These structures contain the
protein clathrin which may be involved in trapping of
the receptor-ligand complex. Subsequently, the coated
pits invaginate to form coated vesicles which rapidly give
rise to uncoated vesicles referred to as endosomes or
receptosomes. The receptosome is a low pH compartment
which promotes ligand-receptor dissociation. At this
point the pathways of endocytotic receptors may diverge,
with some classes of receptors being recycled back to the
cell surface while others are degraded in lysosomes. The
transreticular Golgi system may play a role in this sorting
process (153). One of the major questions concerning
receptor-mediated endocytosis is what signals are in-
volved in triggering receptor internalization, sorting, and
receptor recycling.
Recent attention has focused on phosphorylation of
the receptor proteins as a mechanism of regulating their
intracellular distribution. One well characterized recy-
cling receptor, the transferrin receptor, has indeed been
shown to undergo phosphorylation/dephosphorylation
reactions. The transferrin receptor is an integral mem-
brane glycoprotein composed of two identical subunits
of Mr = 90,000 which are linked by a disulfide bond to
form a dimer (197, 198). This receptor mediates the
endocytosis of transferrin, resulting in cellular uptake of
Fe2+. Recently, it has been reported that endocytosis of
the transferrin receptor can be promoted by phorbol
esters (199, 200). Phorbol ester treatment results in a
redistribution in approximately 50% of the transferrin
receptors from the plasma membrane to an endosome
compartment with no loss in total receptor number. In
HL60 cells this event correlates with an increase in the
phosphorylation state of the transferrin receptor (200,
201). Although phorbol esters and transferrin induce
internalization of transferrin receptors in a nonadditive
fashion, transferrin itself does not promote receptor
phosphorylation. This may suggest that although phos-
phorylation results in receptor internalization, it is not
the primary signal for transferrin-induced receptor en-
docytosis. Recently, Davis et al. (202) have identified
serine 24 as the site on the transferrin receptor phospho-
rylated by protein kinase C.
In contrast to the effects of phorbol esters, recent work
has demonstrated that insulin and various growth factors
can induce the redistribution of transferrin receptors
from an intracellular endosome compartment to the
plasma membrane (203, 204). In view of the observation
that insulin promotes a similar redistribution of IGF-II
receptors by reducing their phosphorylation state (see
above), it is tempting to speculate that insulin and
growth factors induce dephosphorylation of transferrin
receptors leading to their enhanced cell surface expres-
sion.
Other recycling receptors may be regulated by phos-
phorylation events. The asialoglycoprotein receptor is
phosphorylated on serine residues (205, 206) although
the functional significance of this modification is not
known. Phorbol esters have been shown to reduce the
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binding activity of low density lipoprotein (LDL) recep-
tors (207); however receptor phosphorylation was not
examined. In contrast, Kishimoto et al. (208) have dem-
onstrated phosphorylation of the LDL receptor on serine
833 in the cytoplasmic domain by a casein kinase II-like
enzyme purified from adrenal cortex. The physiological
significance of this modification is unknown as mutating
this serine to an alanine has no effect on the rate of LDL
receptor internalization (209).
Receptors Mediating Immune Function
T Lymphocyte Receptors
The T cell antigen receptor is found on T lymphocytes
where it mediates the activation of these cells by specific
antigens. Clonotypic antibodies and cDNA cloning by
subtractive screening methods have shown that the main
core of the receptor is formed of an a (40-50 kD)- and fi
(43 kD)-subunit heterodimer (reviewed in Ref. 210).
However, immunoprecipitation and cross-linking exper-
iments have suggested that the functioning receptor may
involve several additional protein components. A com-
plex of proteins termed the T3 complex has been char-
acterized both in the human and murine systems (211-
214). This complex is comprised of two glycoproteins of
20-22 kD (gp21) and 26 kD (gp26), and two nonglyco-
sylated peptides of 25-26 kD (p25) and 16 kD (pl6). An
additional nonglycosylated subunit of 21 kD (p21) has
recently been identified in the murine system (215).
Activation of the T cell antigen receptor complex by
clonotypic antibodies or specific antigens leads to the
increased hydrolysis of polyphosphoinositides, suggest-
ing that activation of protein kinase C may at least in
part mediate T cell activation (216, 217). Although a
biochemical role for each of the putative components of
the receptor complex has not yet been established, sev-
eral studies have suggested that many of these polypep-
tides are phosphorylated in response to T cell activation
by specific antigens or mitogens. In human T lympho-
cytes, Cantrell et al. (218) have reported phosphorylation
of two peptides of the T3 complex (Mr = 26,000 and to a
lesser extent Mr = 21,000) upon activation of cells with
phorbol esters. Samuelson et al. (215) have shown in
murine T cell hybridomas that phorbol esters lead to
phosphorylation of p25 and gp21 on serine residues.
Antigen activation of these cells leads to the phosphor-
ylation of the same gp21 subunit and a previously uni-
dentified 21 kD polypeptide on tyrosine residues. It has
been speculated that phosphorylation of the various T
cell receptor complex subunits might be involved in the
process of down-regulation or desensitization of the T
cell receptor, a process induced by phorbol esters (218).
Recently, the suggestion has been made (219) that the
phosphorylation pattern of one of these subunits (p21,
tyrosine phosphorylation) may be abnormally constitu-
tive in a mouse model of lymphoproliferative disease.
Thus, these data suggest that phosphorylation of the T
cell antigen receptor complex may modulate several of
its functions.
Another T lymphocyte-specific receptor is that which
binds T cell growth factor (TCGF) or interleukin-2 (IL-
2), a Mr = 14,800 glycopeptide hormone necessary for
antigen- or mitogen-mediated activation of T cell prolif-
eration (220). The receptor for IL-2 is a glycoprotein of
Mr = 55,000 with a nonglycosylated amino acid core of
Mr = 28,428 (220). The mechanisms of signal transduc-
tion for this hormone effector system are still not com-
pletely understood. However, IL-2 has been shown to
induce a redistribution of protein kinase C activity (221),
a property which is shared by hormones that use the
phosphatidylinositol/Ca++ pathway as a transducing
mechanism.
Several studies have documented that the IL-2 recep-
tor is a phosphoprotein. Leonard et al. (222) showed that
human IL-2 receptors isolated from mitogen-stimulated
peripheral lymphocytes and leukemic HUT 102B2 T cells
are constitutively phosphorylated. Shackelford and
Trowbridge (223) have shown that treatment of activated
T cells or leukemic cells with phorbol esters induces the
phosphorylation of the IL-2 receptor which is associated
with increased expression of IL-2 receptors on the sur-
face of these cells. More recently, Gaulton and Eardley
(224) have shown that exposure of mitogen-activated
splenic T cells to physiological concentrations of IL-2
causes rapid phosphorylation of several membrane pro-
teins amongst which is the IL-2 receptor protein itself.
By site-directed mutagenesis, Gallis et al. (225) have
shown that cytoplasmic serine 247 is likely to be the site
of phosphorylation of the IL-2 receptor. From these data
it has been suggested that phosphorylation of the IL-2
receptor may be involved in the expression and mainte-
nance of the receptor at the cell surface.
Immunogbbulin (Ig) receptors
Mast cells and basophils express, on their surface,
specific receptors for IgE. Binding of IgE to these recep-
tors initiates the noncytotoxic release and synthesis of a
variety of chemical mediators of inflammation such as
histamine and leukotrienes from these cells (226). The
IgE receptor is heterotetramer composed of one a (45
kD)-, one fi (33 kD)-, and two 7-subunits (9 kD) (226).
The a-subunit is thought to be extracellular and serves
as the ligand binding site for IgE whereas the j8-subunit
appears to be transmembrane. The two 7-subunits inter-
act with the jS-subunit within the cytoplasmic domain
(226).
The biochemical signalling mechanisms by which IgE
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initiates its effects are still poorly understood; nonethe-
less, phosphorylation of the IgE receptor has been ex-
amined as a possible control mechanism for IgE-me-
diated effects. Hempstead et al. (227, 228) have reported
that in normal rat mast cells, the a- and /3-subunits of
the receptor are constitutively phosphorylated. Antigen
activation of these cells results in increased phosphor-
ylation of the a-subunit whereas the 0-subunit phos-
phorylation is unaltered. The increase in a-subunit phos-
phorylation occurs within the time scale of cell activation
leading to the hypothesis that this covalent modification
is a primary event in receptor action. In contrast, Metz-
ger and colleagues (229, 230), using basophilic leukemia
cells, observed phosphorylation of the /3- and 7-subunits
of the IgE receptor but no phosphorylation of the a-
subunit. In these cells, antigen activation results in in-
creased phosphorylation of the /3-subunit whereas the 7-
subunit phosphorylation is decreased. In light of these
controversial findings, it is clear that more work will be
necessary to define a functional role for IgE receptor
phosphorylation.
Polymeric IgA, the major immunoglobulin in external
secretions, is synthesized in plasma cells of various mu-
cosal tissues as well as exocrine glands (231). Receptors
for IgA are synthesized by a variety of epithelial cells,
including hepatocytes, and mediate the secretion of poly-
IgA via receptor-mediated transport across the epithelia
(232). In hepatocytes, the mature form of the receptor
(120 kD) arises from two intermediate precursors, a 105
kD initial precursor which becomes glycosylated to a 116
kD secondary form. The final maturation of the 116 kD
precursor to the mature 120 kD form is associated with
phosphorylation of the intracellular domain of the recep-
tor on serine residues (233). Whereas this active form of
the IgA receptor appears to be phosphorylated, the bio-
logical significance of this phosphorylation is still not
understood. One possibility is that it is involved in the
sorting patterns and intracellular processing of the re-
ceptor protein (233).
Conclusions
A rapidly expanding body of literature now indicates
that the functionality and/or cellular distribution of cell
surface receptors for hormones, drugs, neurotransmit-
ters, and growth factors can be regulated by phosphor-
ylation. In many instances where phosphorylation di-
rectly alters receptor function, this appears to be in a
negative direction. Thus, receptor phosphorylation may
result in decreased agonist ligand binding or a diminished
ability of the receptor to interact with its biochemical
effector. In some cases, the enzymatic activity of a recep-
tor molecule may be inhibited. In contrast, autophos-
phorylation of the tyrosine kinase receptors may result
in increased enzymatic activity and enhanced receptor
function. In those receptor systems which exhibit inter-
nalization and recycling phenomena, phosphorylation
appears to result in enhanced receptor internalization.
The biological role for this internalization event may be
quite varied and system specific. In some cases, the
consequence of receptor internalization may be dephos-
phorylation and resensitization, whereas in others the
result is enhanced endocytosis of a specific ligand. Future
work in this rapidly growing field will undoubtedly focus
on identifying a role for phosphorylation in other recep-
tor systems, characterizing the protein kinases and phos-
phatases involved, and elucidating the molecular mech-
anisms by which phosphorylation produces its functional
effects.
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